Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elotuzumab + thalidomide + dexamethasone + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen consists of **elotuzumab** (a humanized monoclonal antibody targeting signalling lymphocytic activation molecule family member 7), **thalidomide** (an immunomodulatory agent), **dexamethasone** (a synthetic glucocorticoid corticosteroid), and **cyclophosphamide** (an alkylating agent). Used experimentally for relapsed/refractory multiple myeloma, this combination seeks to improve antitumor activity through multiple mechanisms: elotuzumab stimulates natural killer cells and mediates antibody-dependent cellular cytotoxicity of myeloma cells; thalidomide suppresses angiogenesis and modulates immune response; dexamethasone provides anti-inflammatory and cytotoxic effects; cyclophosphamide causes DNA damage in rapidly dividing cells. In Phase II trials, the regimen was well tolerated and showed moderate efficacy in heavily pre-treated multiple myeloma patients[1][2][5].
- Other names
- elotuzumab + thalidomide + dexamethasone + cyclophosphamide
02
Targets
GR (Glucocorticoid receptor)DNAFCGR3B (Fc gamma receptor III)SLAMF7 (Signaling lymphocytic activation molecule family member 7)CRBN (Cereblon)
Beyond the preview
Go deeper on elotuzumab + thalidomide + dexamethasone + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elotuzumab + thalidomide + dexamethasone + cyclophosphamide.